Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Peginterferon alfa-2a - Roche

Drug Profile

Peginterferon alfa-2a - Roche

Alternative Names: PEG IFN-α-2a; PEG interferon-α-2a; Pegasys; Pegferon; Pegylated interferon-alpha-2a; R 442; RG 442; RG 964; RO 25-8310; RO 253036

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Icahn School of Medicine at Mount Sinai; Roche; University of Pennsylvania
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Immunostimulants; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hepatitis B; Hepatitis C
  • Phase III Chronic myeloid leukaemia; Essential thrombocythaemia; Hepatitis D; Polycythaemia vera
  • Phase II HIV-1 infections
  • Discontinued Malignant melanoma; Renal cell carcinoma

Most Recent Events

  • 28 Jan 2019 No recent reports of development identified for phase-I development in Hepatitis-C in Hong Kong (SC, Injection)
  • 28 Jan 2019 No recent reports of development identified for phase-I development in Hepatitis-C in Taiwan (SC, Injection)
  • 01 Dec 2018 Peginterferon alfa-2a licensed to Ascletis in China
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top